Akari Therapeutics To Report Fourth Quarter and Full Year 2017 Financial and Operational Results and Host Conference Call on ...
March 16 2018 - 8:00AM
Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company
focused on the development and commercialization of innovative
therapeutics to treat orphan autoimmune and inflammatory diseases,
today announced that the Company will report its financial results
for the fourth quarter and full year ended December 31, 2017 on
Wednesday, March 21, 2018 before the U.S. financial markets open.
Following the release of the financial results, Akari Therapeutics
management will conduct a conference call and webcast that morning
at 8:30 a.m. Eastern Time (ET).
The call can be accessed by dialing (844) 461-9933 or (636)
812-6633 (international), and referencing conference ID 2096211.
The conference call will also be webcast live over the Internet and
can be accessed on the "Events & Presentations" page under the
"Investors & Media" section of the Akari Therapeutics website,
www.akaritx.com, prior to the event. A replay of the webcast will
be available for at least 30 days following the call at
www.akaritx.com.
About Akari Therapeutics
Akari is a biopharmaceutical company focused on developing
inhibitors of acute and chronic inflammation, specifically the
complement system, the eicosanoid system and the bioamine system
for the treatment of rare and orphan diseases, in particular those
where the complement system or leukotrienes or both complement and
leukotrienes together play a primary role in disease progression.
Akari's lead drug candidate Coversin is a C5 complement inhibitor
currently being evaluated in paroxysmal nocturnal hemoglobinuria
(PNH) and atypical hemolytic uremic syndrome (aHUS). In addition to
its C5 inhibitory activity, Coversin independently and specifically
inhibits leukotriene B4 (LTB4) activity. Akari intends to evaluate
Coversin in two conditions, the skin and eye diseases bullous
pemphigoid and atopic keratoconjunctivitis, where the dual action
of Coversin on both C5 and LTB4 may be beneficial. Akari is also
developing other tick derived proteins, including long acting
versions.
For more information
Investor Contact:
Peter VozzoWestwicke Partners(443)
213-0505peter.vozzo@westwicke.com
Media Contact:
Mary-Jane Elliott / Sukaina Virji / Nicholas BrownConsilium
Strategic Communications+44 (0)20 3709
5700Akari@consilium-comms.com
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Akari Therapeutics (NASDAQ:AKTX)
Historical Stock Chart
From Sep 2023 to Sep 2024